CKD Bio Statistics

Total Valuation

CKD Bio has a market cap or net worth of KRW 120.69 billion. The enterprise value is 267.47 billion.

Market Cap	120.69B
Enterprise Value	267.47B

Important Dates

The next estimated earnings date is Tuesday, March 4, 2025.

Earnings Date	Mar 4, 2025
Ex-Dividend Date	n/a

Share Statistics

CKD Bio has 5.49 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	5.49M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.05%
Owned by Institutions (%)	0.95%
Float	3.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.75
PB Ratio	0.92
P/TBV Ratio	0.96
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.56
EV / Sales	1.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.72

Financial Position

The company has a current ratio of 1.56, with a Debt / Equity ratio of 1.21.

Current Ratio	1.56
Quick Ratio	0.65
Debt / Equity	1.21
Debt / EBITDA	n/a
Debt / FCF	-6.97
Interest Coverage	-5.49

Financial Efficiency

Return on equity (ROE) is -16.26% and return on invested capital (ROIC) is -5.54%.

Return on Equity (ROE)	-16.26%
Return on Assets (ROA)	-4.96%
Return on Capital (ROIC)	-5.54%
Revenue Per Employee	308.16M
Profits Per Employee	-44.57M
Employee Count	519
Asset Turnover	0.51
Inventory Turnover	2.04

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +2.03% in the last 52 weeks. The beta is 1.12, so CKD Bio's price volatility has been higher than the market average.

Beta (5Y)	1.12
52-Week Price Change	+2.03%
50-Day Moving Average	24,218.60
200-Day Moving Average	24,880.90
Relative Strength Index (RSI)	44.55
Average Volume (20 Days)	15,556

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CKD Bio had revenue of KRW 159.93 billion and -23.13 billion in losses. Loss per share was -4,216.38.

Revenue	159.93B
Gross Profit	6.95B
Operating Income	-25.06B
Pretax Income	-26.79B
Net Income	-23.13B
EBITDA	-7.40B
EBIT	-25.06B
Loss Per Share	-4,216.38

Full Income Statement

Balance Sheet

The company has 12.35 billion in cash and 159.13 billion in debt, giving a net cash position of -146.78 billion or -26,755.58 per share.

Cash & Cash Equivalents	12.35B
Total Debt	159.13B
Net Cash	-146.78B
Net Cash Per Share	-26,755.58
Equity (Book Value)	131.58B
Book Value Per Share	23,985.21
Working Capital	48.83B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -16.59 billion and capital expenditures -6.24 billion, giving a free cash flow of -22.83 billion.

Operating Cash Flow	-16.59B
Capital Expenditures	-6.24B
Free Cash Flow	-22.83B
FCF Per Share	-4,161.57

Full Cash Flow Statement

Margins

Gross margin is 4.35%, with operating and profit margins of -15.67% and -14.46%.

Gross Margin	4.35%
Operating Margin	-15.67%
Pretax Margin	-16.75%
Profit Margin	-14.46%
EBITDA Margin	-4.63%
EBIT Margin	-15.67%
FCF Margin	n/a

Dividends & Yields

CKD Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.02%
Shareholder Yield	0.02%
Earnings Yield	-19.17%
FCF Yield	-18.92%

Dividend Details

Stock Splits

The last stock split was on December 27, 2019. It was a forward split with a ratio of 1.05.

Last Split Date	Dec 27, 2019
Split Type	Forward
Split Ratio	1.05

Scores

CKD Bio has an Altman Z-Score of 1.23. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.23
Piotroski F-Score	n/a